Short Interest in PainReform Ltd. (NASDAQ:PRFX) Drops By 37.9%

PainReform Ltd. (NASDAQ:PRFX) was the recipient of a significant drop in short interest in March. As of March 31st, there was short interest totalling 38,600 shares, a drop of 37.9% from the March 15th total of 62,200 shares. Approximately 2.3% of the company’s shares are sold short. Based on an average daily volume of 1,050,000 shares, the days-to-cover ratio is currently 0.0 days.

Hedge Funds Weigh In On PainReform

A hedge fund recently bought a new stake in PainReform stock. Apollon Wealth Management LLC bought a new position in shares of PainReform Ltd. (NASDAQ:PRFX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 12,917 shares of the company’s stock, valued at approximately $43,000. Apollon Wealth Management LLC owned about 9.23% of PainReform as of its most recent SEC filing. Institutional investors own 37.28% of the company’s stock.

PainReform Stock Performance

Shares of NASDAQ:PRFX traded up $0.00 during midday trading on Thursday, hitting $1.99. 31,383 shares of the stock were exchanged, compared to its average volume of 1,966,824. The business’s 50-day moving average price is $2.65 and its 200 day moving average price is $2.91. PainReform has a 12 month low of $1.68 and a 12 month high of $23.27. The stock has a market capitalization of $1.74 million, a price-to-earnings ratio of -0.01 and a beta of 0.72.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.